美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.63

-0.4962-1.41%

成交量：1.73萬

成交額：60.10萬

市值：9,627.03萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.53

換手率：0.62%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

藥捷安康-B(02617.HK)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥

藥捷安康-B(02617)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥

開源證券：原料藥板塊業績增速企穩回升創新藥及CDMO轉型公司進入兑現期

朱保國卸任、公司業績下滑，39歲劉大平能否改變麗珠困局？

460倍淨利潤增幅：全球咖啡因龍頭會成A股創新藥老大嗎？

立方製藥(003020.SZ)：塞來昔布鹽酸曲馬多片藥品註冊臨床試驗申請獲得受理

立方製藥：臨床試驗申請獲受理，受理號CYHL2600101

甘李藥業(603087.SH)：在研藥品GLR1075注射液獲藥物臨床試驗批准

甘李藥業：GLR1075注射液獲臨床試驗批准

創新藥板塊迎利好業績有望持續高增長股名單出爐

利好！十部門聯合發布，創新藥大漲！

重磅政策利好！多股10CM漲停

利好來了！十部門聯合發布

工信部等十部門聯合發布《醫藥工業發展「十五五」規劃》

《醫藥工業發展「十五五」規劃》發布創新藥產業規模年均增速將超20%

「十五五」時期我國首創新藥佔全球比例將達到25%以上

創新藥、農業板塊逆勢走強結構性機會仍是短期市場主基調

大众证券报

加息落地、A股承壓，創新藥為何仍有韌性？

我國今年以來已批准上市創新藥59個

百利天恒(688506.SH)子公司擬500萬美元投資創新藥企業Connexus Therapeutics

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6296,"timestamp":1789749770583,"preClose":35.1258,"halted":0,"volume":17295,"delay":0,"changeRate":-0.014126368652101722,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"交易中","change":-0.4962,"latestTime":"09-18 12:46:29 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":600953.55039,"amplitude":0.014246,"askPrice":34.69,"askSize":3200,"bidPrice":34.66,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007419,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.14,"preClose":35.1258,"latestTime":"19:58 EDT","volume":117,"amount":4061.8054,"timestamp":1789689522745,"change":0.0142,"changeRate":0.000404,"amplitude":0},"volumeRatio":1.53072,"impliedVol":0.1125,"impliedVolPercentile":0.4821},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.53072,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6296,"committee":-0.641026,"eps":0,"divideRate":0.007419,"volume":17295,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668940687","title":"藥捷安康-B(02617.HK)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940687?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668894069","title":"藥捷安康-B(02617)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2668894069","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668894069?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，本公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验，于近日完成首例患者给药。其中新型内分泌治疗药物虽可显著延长患者生存期，为当前mCRPC一线核心治疗方案，但绝大多数患者最终会发生获得性耐药。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBJ","MDTX","02617","BK1161","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668965944","title":"開源證券：原料藥板塊業績增速企穩回升 創新藥及CDMO轉型公司進入兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2668965944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668965944?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 17:28","pubTimestamp":1789723709,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开源证券发布研报称，国内原料药行业逐渐企稳回升，部分公司积极布局创新药赛道，持续拓展公司天花板，有望进入收获期。开源证券主要观点如下：原料药板块：业绩增速企稳回升，创新药及CDMO转型公司进入兑现期随着原料药行业去库存逐步完成、落后产能加速出清，板块基本面开始出现改善迹象，营收及净利润已逐步触底回升，毛利率相对稳定，估值水平呈现修复趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","BK1574","BK4139","159992","BK1161","06978","CDMO","LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668417979","title":"朱保國卸任、公司業績下滑，39歲劉大平能否改變麗珠困局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2668417979","media":"市场资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668417979?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 17:08","pubTimestamp":1789722480,"startTime":"0","endTime":"0","summary":"朱保国辞任董事长后，丽珠集团总裁39岁的刘大平被推举为新任董事长，接过这家老牌医药企业的掌舵权。2026年9月11日，朱保国宣布退休，一同辞去了丽珠集团以及健康元董事长在内的所有职务。接替朱保国担任丽珠集团董事长的是公司总裁39岁的刘大平。分季度来看，丽珠集团业绩下行压力在第二季度进一步放大，第二季度，公司营收同比下降31.14%，归母净利润同比下降44.86%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-18/doc-inisfyex3432880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","IBBQ","BK1161","BK1574","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668594676","title":"460倍淨利潤增幅：全球咖啡因龍頭會成A股創新藥老大嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2668594676","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668594676?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 16:11","pubTimestamp":1789719060,"startTime":"0","endTime":"0","summary":"赵蓓管理的工银瑞信前沿医疗，在迄今持仓的六个季度中，大致保持了对石药创新的仓位稳定。近期以创新药和CXO为首的医药板块热度再次上扬，成为非科技赛道中亮眼的存在。但医药板块中标的相 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260918/c680060109.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260918/c680060109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06978","MEDX","159992","159982","IBBQ","03188","LNGR","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668945000","title":"立方製藥(003020.SZ)：塞來昔布鹽酸曲馬多片藥品註冊臨床試驗申請獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2668945000","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668945000?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 15:53","pubTimestamp":1789718035,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)发布公告，近日，公司收到国家药品监督管理局下发的塞来昔布盐酸曲马多片药品注册临床试验申请《受理通知书》。塞来昔布盐酸曲马多片是由阿片类激动剂盐酸曲马多与非甾体抗炎药塞来昔布形成的共晶。本次申请药品注册临床试验的拟定适应症为：适用于治疗成人短期中度至重度急性躯体性疼痛。中度至重度躯体疼痛包括术后疼痛(例如骨科和创伤外科手术，或牙科手术后)或肌肉骨骼疼痛(肌肉、韧带、肌腱和关节损伤)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","003020","MDTX","IBBJ","BK0250","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668945096","title":"立方製藥：臨床試驗申請獲受理，受理號CYHL2600101","url":"https://stock-news.laohu8.com/highlight/detail?id=2668945096","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668945096?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 15:51","pubTimestamp":1789717866,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","MDTX","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668417945","title":"甘李藥業(603087.SH)：在研藥品GLR1075注射液獲藥物臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668417945","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668417945?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 15:37","pubTimestamp":1789717057,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)下发的关于在研药品GLR1075注射液的《药物临床试验批准通知书》，经审查，2026年7月3日受理的GLR1075注射液临床试验申请符合药品注册的有关要求，同意本品开展肝硬化腹水低白蛋白血症的临床试验。GLR1075注射液是甘李药业自主研发的重组人白蛋白制剂，属于人源化重组蛋白药物。其活性成分重组人白蛋白与天然人血清白蛋白具有相同的氨基酸序列和相似的空间构象，可发挥白蛋白的核心生理功能，包括纠正胶体渗透压失衡、改善病理微环境等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","BK0239","MDTX","IBBJ","603087","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668945627","title":"甘李藥業：GLR1075注射液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668945627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668945627?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 15:34","pubTimestamp":1789716891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","IBBQ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668175759","title":"創新藥板塊迎利好 業績有望持續高增長股名單出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=2668175759","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668175759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 12:49","pubTimestamp":1789706976,"startTime":"0","endTime":"0","summary":"据数据宝，工业和信息化部等十部门联合发布的《医药工业发展“十五五”规划》（简称《规划》）提出，到2030年，生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。展望下半年，平安医药精选基金经理周思聪认为创新药有望成为重要成长主线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878466228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878466228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","BK1161","IBBQ","159992","06978","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668691152","title":"利好！十部門聯合發布，創新藥大漲！","url":"https://stock-news.laohu8.com/highlight/detail?id=2668691152","media":"同花顺","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668691152?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 10:41","pubTimestamp":1789699260,"startTime":"0","endTime":"0","summary":"【导读】创新药板块早盘短线冲高，南华生物涨停9月18日，创新药板块早盘短线冲高，泓博医药涨超15%，南华生物、贝瑞基因涨停，百普赛斯、诺禾致源、百克生物等纷纷走高。消息面上，9月18日 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260918/c680047720.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260918/c680047720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06978","MEDX","BK1161","LNGR","IBBQ","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668812919","title":"重磅政策利好！多股10CM漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2668812919","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668812919?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 10:02","pubTimestamp":1789696970,"startTime":"0","endTime":"0","summary":"追高要谨慎","market":"sg","thumbnail":"https://img3.gelonghui.com/0ba02-1248a6cf-b90b-4c11-939f-ffb275c0e95f.jpg?guru_height=718&guru_width=1280&guru_size=117718","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/0ba02-1248a6cf-b90b-4c11-939f-ffb275c0e95f.jpg?guru_height=718&guru_width=1280&guru_size=117718"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6705961","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","LNGR","IBBQ","BK1574","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919378","title":"利好來了！十部門聯合發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919378","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668919378?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:55","pubTimestamp":1789696500,"startTime":"0","endTime":"0","summary":"工信部等十部门印发《医药工业发展“十五五”规划》，创新药产业规模年均增速将超20%。9月18日，工业和信息化部、国家发展改革委等十部门联合发布《医药工业发展“十五五”规划》(下称《规 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260918/c680044901.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260918/c680044901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBQ","LNGR","BK1574","BK1161","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668915235","title":"工信部等十部門聯合發布《醫藥工業發展「十五五」規劃》","url":"https://stock-news.laohu8.com/highlight/detail?id=2668915235","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668915235?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:07","pubTimestamp":1789693621,"startTime":"0","endTime":"0","summary":"同时，《规划》围绕产业规模效益、创新发展、企业培育与集群发展等方面提出规模以上医药工业企业营业收入、研发投入强度、创新药械上市数量、龙头企业与千亿级园区培育等10项预期性指标。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YTI1MmE4Njc2MTkyMDEyMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YTI1MmE4Njc2MTkyMDEyMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991918","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668915935","title":"《醫藥工業發展「十五五」規劃》發布 創新藥產業規模年均增速將超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668915935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668915935?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:02","pubTimestamp":1789693326,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","LNGR","159992","BK1161","06978","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668091656","title":"「十五五」時期我國首創新藥佔全球比例將達到25%以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2668091656","media":"央视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668091656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:00","pubTimestamp":1789693200,"startTime":"0","endTime":"0","summary":"工业和信息化部、国家发展改革委等十部门今天联合发布《医药工业发展“十五五”规划》。《规划》重点围绕产业规模效益、创新发展、企业培育和集群发展等方面提出了“十五五”时期医药工业发展预期性指标。在创新发展方面，《规划》提出的目标是：医药工业上市企业平均研发投入强度年均达到10%以上，首创新药占全球比例达到25%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-18/doc-inisfazf3488675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","MEDX","BK1161","IBBQ","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668939779","title":"創新藥、農業板塊逆勢走強 結構性機會仍是短期市場主基調","url":"https://stock-news.laohu8.com/highlight/detail?id=2668939779","media":"大众证券报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668939779?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 22:10","pubTimestamp":1789654200,"startTime":"0","endTime":"0","summary":"盘面上，创新药、农业、汽车、航运等板块逆势走强，贵金属、石油石化、电力等周期板块承压回调，前一日领涨的科技赛道内部出现明显分化。消费成长板块领涨9月17日，A股市场震荡调整。上涨动力源于诺和诺德与Anthropic达成AI药物研发合作的消息催化，行业头部企业盈利改善、临床数据逐步验证，创新药产业链长期价值获资金认可。展望后市，机构普遍认为结构性机会仍是主基调，配置上需兼顾进攻与防御。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-17/doc-inisczpy9091282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159041","159992","LNGR","BK1161","IBBQ","MEDX","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967049","title":"加息落地、A股承壓，創新藥為何仍有韌性？","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967049","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668967049?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 20:52","pubTimestamp":1789649520,"startTime":"0","endTime":"0","summary":"港股方面，创新药等相关医药板块亦表现活跃。面对这样的盘面，可能不少朋友都会有一个疑问：美联储加息落地后，A股整体表现承压；作为利率相对敏感的成长方向，创新药为何仍能表现出一定韧性？加息落地后，后续政策仍有变数，海外流动性尚未明确转向宽松。对创新药而言，外部扰动仍在，短期或仍会受利率和风险偏好影响。而这种产业内生的确定性，或许也正是创新药在宏观扰动下仍能展现出一定韧性的底气所在。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjzl/2026-09-17/doc-inisczpx0332234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03130","TMF","02827","US2Y.BOND","159992","07233","02846","83130","US12M.BOND","US10Y.BOND","US6M.BOND","03188","LNGR","83188","US30Y.BOND","IBBQ","MEDX","US5Y.BOND","US7Y.BOND","06978","82846","TLT","BK1574","BK1161","399300","159982","BK1147","US3Y.BOND","TLTW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668962513","title":"我國今年以來已批准上市創新藥59個","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668962513?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 20:24","pubTimestamp":1789647853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MEDX","IPOS","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964804","title":"百利天恒(688506.SH)子公司擬500萬美元投資創新藥企業Connexus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668964804?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 19:44","pubTimestamp":1789645459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，为拓宽公司在除创新ADC药物研发平台，创新多特异性抗体药物研发平台，以及特异性增强双特异性抗体平台及创新ARC(核药)研发平台以外其他前沿技术赛道的布局，补充公司技术矩阵。公司全资子公司盘古资本拟以500万美元认购Connexus Therapeutics388.1万股A轮优先股股份，本次增资完成后，公司将持有Connexus 7.91%股权。Connexus是一家创新药企业，专注于肿瘤领域小分子药物的开发，其在研项目均处于临床前研发阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91194","159992","MEDX","688506","BK1161","BK4139","BK4539","LENZ","IBBQ","LNGR","BK4007","BK1574","BK0239","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":219,"code":"91000000","status":"200"}]}}